TORONTO, May 20 /CNW/ - Amorfix Life Sciences (TSX:AMF), a company
focused on treatments and diagnostics for misfolded protein diseases announced
it has initiated the second phase of its large-scale study in France to
demonstrate the feasibility of routine testing of blood donations for vCJD.
Amorfix's EP-vCJD(TM) test has been transferred to the Etablissement Français
du Sang de Pyrénées Méditerrannée (EFS-PM) in Montpellier, France for the
testing of an additional 20,000 blood donor samples.
Results from testing 20,000 blood donations in the first phase of the
study conducted in Strasbourg (with Professor Jean-Pierre Cazenave) will be
reported in a paper on June 24, 2009, at le Congrès 2009 de la Société
Française de Transfusion Sanguine.
"Equipment set up and training of technicians were completed smoothly and
we are pleased to be continuing the study in Montpellier with Dr. Joliette
Coste, the Scientific Director of EFS-PM," said Dr. George Adams, CEO of
Amorfix. "The routine testing of blood donations for vCJD in any country would
require millions of samples to be screened annually at several blood centers.
It is important to show the test system can be established easily and perform
well at multiple sites and on numerous samples."
In related news, the process to define a CE mark for a blood screening
test for vCJD reached a major milestone. The European Union's vCJD Experts
Working Group met April 29, 2009 and completed the draft Common Technical
Specifications (CTS) and guideline. These draft documents outline the
requirements for CE marking of IVDs for vCJD, are now ready for adoption by
the IVD Technical Group at their September meeting.
Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing
therapeutic products and diagnostic devices targeting misfolded diseases
including neurodegenerative diseases and cancer. It has specific programs in
vCJD, ALS and Alzheimer's Disease. Amorfix's proprietary Epitope
Protection(TM) (EP) technology enables it to specifically identify very low
levels of aggregated misfolded proteins (AMP) in a sample containing normal
protein. Aggregated misfolded proteins are a common element of many brain
wasting diseases and cancer. Amorfix has shown antibodies and vaccines to
misfolded proteins are therapeutic in preclinical animal models. Amorfix's
lead programs are a diagnostic blood screening test for vCJD and a therapy for
This information release may contain certain forward-looking information.
Such information involves known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements to be
materially different from those implied by statements herein, and therefore
these statements should not be read as guarantees of future performance or
results. All forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently available to
it as well as other factors. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks and
uncertainties identified by the Company in its public securities filings,
actual events may differ materially from current expectations. The Company
disclaims any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
For further information:
For further information: Dr. George Adams, President & Chief Executive
Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6959, Fax: (416) 847-6899,
firstname.lastname@example.org; James Parsons, Chief Financial Officer, Amorfix Life
Sciences Ltd., Tel: (416) 847-6929, Fax: (416) 847-6899,